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3ABSTRACT
Accelerated atherosclerosis is a complication of the autoimmune rheumatic disease systemic
lupus erythematosus (SLE). We questioned the role played by invariant Natural Killer T-(iNKT)
cells in this process, since they are defective in autoimmunity but also promote atherosclerosis in
response to CD1d-mediated lipid-antigen presentation. iNKT-cells from SLE patients with
asymptomatic plaque (SLE-P) had increased proliferation and IL-4 production compared to SLE
patients with no plaque. The anti-inflammatory iNKT-cell phenotype was associated with
dyslipidaemia and was driven by altered monocyte phospholipid expression and CD1d-mediated
cross-talk between iNKT-cells and monocytes but not B-cells. Healthy iNKT-cells differentiated
in the presence of healthy monocytes and SLE-P serum polarized macrophages towards an anti-
inflammatory M2-phenotype. Conversely, patients with clinical cardiovascular disease had
unresponsive iNKT-cells and increased pro-inflammatory monocytes. iNKT-cell function could
link immune responses, lipids and cardiovascular disease in SLE patients and, together with
serum lipid taxonomy help predict pre-clinical atherosclerosis in SLE patients.
4ABBREVIATIONS
 α-GalCer, α-galactosylceramide; APC, antigen presenting cells; CTB,  cholera-toxin B; CVD, 
cardiovascular disease; GSM, Grey Scale Median; HDL, high density lipoprotein; iNKT cells,
IDL intermediate density lipoprotein; IMT, intima-media thickness; invariant Natural Killer T
cells; iTCR, invariant T cell receptor; LDL, low density lipoprotein; PB, peripheral blood;
PBMC, peripheral blood mononuclear cells; PD-1, Programmed cell death protein 1; PPBP, Pro-
platelet basic protein; STAT-1, Signal transducer and activator of transcription 1; SLE, systemic
lupus erythematosus; SLE-P, SLE patients with plaque; SLE-NP, SLE patients without plaque;
SLE-CV, SLE patients with cardiovascular disease; VLDL, very low density lipoprotein;
5INTRODUCTION
Atherosclerosis is a chronic inflammatory disease of the large arteries, characterized by defects
in lipid homeostasis. Oxidized lipid antigens within atherosclerotic plaques contribute to disease
progression through macrophage differentiation, lipid-antigen presentation and activation of T
cell responses. Patients with systemic lupus erythematosus (SLE) have an increased risk of
atherosclerosis compared to the general population with female patients aged 35-44 years being
over 50 times more likely to experience a cardiovascular event compared to age-matched female
controls (1). Whilst traditional cardiovascular risk factors (including smoking and hypertension)
are common in SLE patients (2), they do not account for the increased cardiovascular risk which
may be due to persistent inflammation and immune cell dysfunction (3). Dyslipidemia is a
conventional risk factor for cardiovascular disease (CVD), but lipids also have potent effects on
the immune system. SLE patients have multiple lipid defects including dyslipidemia (3) and
altered plasma membrane glycosphingolipid profiles that contribute to abnormal immune cell
function (4, 5).
Invariant Natural Killer T (iNKT) cells constitute less than 0.1% of peripheral blood
mononuclear cells (PBMC) and are identified by expression of the Vα24Jα18 invariant T cell
receptor (iTCR) recognizing glycolipid antigen presented via CD1d on antigen presenting cells
(APC). iNKT cells mediate a balance between immune activation and tolerance through
proliferation and rapid release of both pro- and anti-inflammatory cytokines, resulting in immune
cell transactivation and modulation (6). They are implicated in the pathogenesis of many diseases
including autoimmunity, cancer, atherosclerosis and allergy (7).
6SLE patients have reduced iNKT cell number and defective function, supporting a protective role
for iNKT cells in autoimmunity. Functional defects, whereby iNKT cells fail to proliferate upon
stimulation with the sponge-derived iNKT cell agonist α-galactosylceramide (α-GalCer) have 
been attributed to defective CD1d-mediated lipid-antigen presentation in SLE patients (8, 9).
While several observations support a role for iNKT cells in promoting atherogenesis (10-12),
iNKT cells may play a regulatory role during its early stages by promoting atherosclerosis
resolution via increased IL-10 production (13). Consequentially, the role of iNKT cells in human
atherogenesis remains unclear.
Understanding the progression of subclinical atherosclerotic plaque is important clinically for
long-term CVD outcomes in SLE patients (14). We investigated the role of iNKT cells in the
development of subclinical atherosclerosis in 100 patients with SLE who had no previous history
of CVD using vascular ultrasound to quantify the presence of plaque and its composition. In our
SLE patient cohort, 36% had subclinical plaque, supporting previous studies (15). SLE patients
with pre-clinical plaque (SLE-P) had a distinct anti-inflammatory iNKT cell profile characterized
by increased activation and IL-4 production which correlated with serum lipid expression levels
and altered lipoprotein composition. Crucially iNKT cells differentiated in the presence of serum
from SLE-P patients induced the polarization of M2-like macrophages in vitro. This protective
iNKT cell phenotype was lost in SLE patients who had a cardiovascular event. The results
support an athero-protective role for iNKT cells driven by serum lipids during the early stages of
atherosclerosis which was lost or overwhelmed during the development of clinical
atherosclerosis. Furthermore, differences in serum lipid taxonomy were sufficient to cluster
7patients with and without pre-clinical plaque and together with iNKT cell phenotype could be
used to predict atherosclerosis development in SLE patients.
8RESULTS
A distinct iNKT cell phenotype in SLE patients with pre-clinical plaque
We examined peripheral blood (PB) iNKT cell frequency and function in SLE patients assessed
for pre-clinical atherosclerosis by carotid and femoral artery ultrasound scan (Supplementary
Methods). SLE patients with asymptomatic plaques (SLE-P) were older, had longer disease
duration and higher mean systolic blood pressure compared to SLE patients without plaque
(SLE-NP), however, no association between plaque presence and current or persistent disease
activity, medication or anti-dsDNA antibody or C3 levels were seen (table S1). Healthy donors
(HC, who were not scanned) were selected based on their gender, age, smoking status and
cardiovascular history which indicated that they were unlikely to have plaque (table S1).
PB iNKT cell frequency was significantly reduced in SLE-NP patients compared to HCs
confirming previous observations (8, 9) however, this reduction was lost in SLE-P patients (Fig.
1A, 1B and fig. S1A for gating strategy). This discrepancy was not explained by associations
with age, disease duration, systolic blood pressure, treatment (9) or other clinical features and
was stable over time (fig. S1B-E and table S1). iNKT cells from SLE-P patients also
preferentially produced IL-4 (Fig. 1C and D) and had a significantly lower IFN-ɣ: IL-4 
production ratio (Fig. 1E) compared to SLE-NP patients and HC. This was corroborated by an
increased expression of Th2 transcription factor GATA-3 (GATA-binding protein 3) compared
to Th1-associated T-Bet (T-box transcription factor) (Fig. 1F and G).
Increased iNKT cell frequency and IL-4 production in SLE-P compared to SLE-NP patients was
associated with a switch towards CD4 positivity, a significant decrease in double negative (CD4-
CD8-) iNKT cells (fig. S2A and B), significantly elevated CD69 and reduced CD161 (NK
marker) and PD-1 (Programmed cell death protein 1) expression levels (fig. S2C and D). This
9phenotype was not recapitulated in conventional CD3+CD4+ or CD3+CD8+ T cells (Fig. S2E and
S2F).
Increased iNKT cell activation in SLE-P patients was corroborated in vitro by testing their
proliferative capacity in response to α-GalCer (a potent iNKT cell agonist) and IL-2. SLE-P
patients had increased expression of cell proliferation marker Ki-67 and increased iNKT cell
frequency, similar to the HCs, showing that they had proliferated in response to α-GalCer/IL-2 
(Fig. 1H-J) and indicating that they had an altered functional potential compared to SLE-NP cells
that did not proliferate as shown previously (9). Furthermore, costimulatory molecule ICOS
(inducible T-cell co-stimulator), previously associated with anti-inflammatory responses, was
significantly elevated in SLE-P compared to SLE-NP iNKT cells, while no differences were seen
in the expression of CD40L following α-GalCer stimulation (Fig. 1K). Thus iNKT cell frequency
and function was altered in SLE patients with sub-clinical atherosclerosis compared to SLE-NP
patients.
Dyslipidaemia correlated with iNKT cell phenotype in SLE-P patients
We reasoned that serum factors could drive differential iNKT cell phenotype and function
between SLE-P and SLE-NP patients. To test this we cultured healthy donor PBMCs with serum
from SLE-P patients, SLE-NP patients or heterologous HCs. Only serum from SLE-P patients
induced increased iNKT cell expansion and IL-4 production similar to the ex vivo iNKT cell
phenotype seen in SLE patients with pre-clinical plaque (Fig. 2A-D). This was prevented by the
addition of blocking anti-CD1d antibody (Fig. 2E) indicating that lipid antigen presentation was
required for the differential iNKT cell activation in SLE-P patients.
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Since no differences in serum cytokine levels were detected between SLE-P and SLE-NP
patients (fig. S3A and table S2) we next assessed whether dyslipidaemia, a risk factor for
atherosclerosis, was associated with the altered iNKT cell activation in SLE-P patients. Serum
lipid composition analyzed using proton nuclear magnetic resonance spectroscopy (16) revealed
elevated concentrations of VLDL but not IDL, LDL or HDL particles in SLE-P compared to
SLE-NP patients (Fig. 2F and fig. S3B). Furthermore, significant differences were detected in
the proportions of free cholesterol, cholesterol esters, phospholipids and triglycerides carried by
lipoprotein subclasses (particularly in VLDL lipoproteins) as well as other serum metabolomic
components in SLE-P compared to SLE-NP patients (Fig. 2F, fig. S3C and table S23).
Supervised hierarchical clustering showed that differences in metabolite expression between
patients with and without pre-clinical plaque were sufficient for the two patient groups to be
segregated (Figure S4). In comparison, serum lipid measures quantified in the clinical laboratory
as part of routine patient management were within normal clinical ranges for our hospital. Only
triglyceride levels and total cholesterol:HDL ratios were significantly elevated in SLE-P patients
compared to SLE-NP patients, consistent with these being risk factors for atherosclerosis
development, although no relationship with iNKT cell frequency was detected (Table S34).
iNKT cell frequency was inversely correlated with free cholesterol and phospholipid content in
VLDL particles in the SLE-P but not the SLE-NP patients (Fig. 2G and table S45) and a strong
positive correlation was observed between iNKT-cell IL-4 production and serum lipids including
triglycerides, cholesterol:HDL ratio and total fatty acid ratios in SLE-P but not the SLE-NP
patients (Fig. 2H and 2I and table S45). Interestingly, serum and isolated serum VLDL/LDL
from SLE-NP patients increased phospholipid accumulation in HC monocytes but not B cells
compared to serum from SLE-P patients and heterogeneous HCs (Fig. 2J and 2K). Thus, serum
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from SLE-P patients was able to recapitulate the iNKT cell phenotype associated with pre-
clinical atherosclerosis in cells from HCs and this was associated with dyslipidemia.
Monocyte lipid-antigen presentation triggers anti-inflammatory iNKT cell responses in
SLE-P patients
The results suggested that changes in CD1d-mediated lipid antigen presentation by APCs could
be influencing differential iNKT cell function. Therefore we isolated cellular lipids from purified
ex vivo monocytes and B cells from SLE-NP, SLE-P and HCs (Fig. 3A for experimental plan).
Initial experiments established that iNKT cells from healthy donors responded more robustly to
lipid fraction 5 (F5) containing phospholipids and sphingomyelin regardless of whether lipids
were isolated from monocytes or B cells (Fig. 3B). However, only monocyte-F5-lipids isolated
from SLE-P patients induced a significant increase in iNKT cell expansion (Fig. 3C and 3D) and
a more anti-inflammatory cytokine environment, characterized by increased IL-4, IL-13 and
reduced IFN-ɣ in tissue culture supernatants compared to SLE-NP patients or controls (Fig. 3E); 
responses that were also reversed by the addition of anti-CD1d antibody (Fig. 3F and 3G).
Thus the results suggested that F5 lipids presented via monocyte, rather than B cell, CD1d were
more effective at inducing iNKT cell activation in SLE-P patients compared to those presented
by SLE-NP patients and that this triggered the production of anti-inflammatory and potentially
athero-protective cytokines (17, 18).
iNKT cells from SLE-P patients support M2 monocyte/macrophage polarization
Since monocytes are central players in the pathogenesis of atherosclerosis and express high
levels of CD1d, we examined their role in iNKT cell activation in more detail. No significant
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differences in the expression of monocyte CD36, LDL-receptor(R), LOX-1 (oxidized low-
density lipoprotein receptor-1) and LRP-1 (Low density lipoprotein receptor-related protein-1),
receptors that facilitate lipid uptake from the microenvironment or CD1d, were detected between
HCs and SLE patients (fig. S5). However, using a combination of monocyte gating strategies we
observed that monocytes from SLE-P patients were less inflammatory compared to SLE-NP
patients. Pro-inflammatory intermediate monocytes (CD14++CD16+)(19) were significantly
increased in SLE-NP patients compared to HCs and SLE-P patients (Fig. 4A and 4B). Moreover,
using the monocyte phenotyping strategy described by Fadini et al (20) the M1:M2 monocyte
ratio was significantly elevated in SLE-NP compared to SLE-P patients and HCs, driven by
increased M1-like (CD14+CD68+CCR2+) and reduced M2-like (CD14+CD206+CX3CR1+)
monocyte frequencies in SLE-NP patients compared to HCs and SLE-P patients (Fig. 4C-F).
We investigated whether serum from SLE-P, SLE-NP patients and HCs could influence
monocyte/macrophage polarization. Strikingly, serum in the absence of T cells had no effect on
in vitro polarization of M2 macrophages/monocytes detected by CD206 (mannose receptor)
which is regulated by IL-4 (21) (Fig. 4G and 4H). However, co-culture of purified monocytes
and T cells (containing iNKT cells) from HCs with SLE-P serum (but not SLE-NP or HC serum)
preferentially induced the polarization of CD206+ M2 macrophages (Fig. 4I for experimental
strategy and 4J). This was associated with concomitant increase in CD206 gene expression and
reduced expression of M1-associated STAT-1 (Signal transducer and activator of transcription 1)
expression (Fig. 4K).
To establish the role of iNKT cells in driving this process we differentiated iNKT cells with
SLE-P and SLE-NP serum then co-cultured the pre-conditioned iNKT cells with human THP-1
macrophages (22) (in order to exclude differences between macrophages derived from healthy
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donor PBMCs). Only iNKT cells exposed to monocytes and SLE-P serum induced upregulation
of CD206 and down regulation of STAT-1 genes associated with M2 and M1 macrophage
polarization respectively, while no differential effect was observed with expression of other M2
(CD200R) and M1 (PPBP (Pro-platelet basic protein) or CD80) macrophage-associated genes
(23, 24) (Fig. 4K for experimental strategy, 4L). However, blocking IL-4 using anti-IL-4
blocking antibody increased STAT-1 and CD80 gene expression compared to isotype control but
did not significantly influence CD206 expression and no differential effect was observed
between the patient groups (Fig. 4N and4O) suggesting that increased M2 monocyte/macrophage
polarisation was not exclusively IL-4 mediated.
SLE patients with clinical cardiovascular disease lost their ‘anti-inflammatory’ iNKT cell
profile
The results indicated that iNKT cells had an athero-protective response in SLE patients with sub-
clinical plaque. Stratification of SLE-P patients according to number of plaque sites, revealed a
strong relationship between iNKT cell phenotype and plaque echolucency, a gauge of plaque
stability and lipid content measured by Grey Scale Median (GSM, supplemental methods for
description of GSM assessment (25)). In patients with 1-2 plaque sites, more stable and less
echolucent plaques (higher GSM score) correlated positively with iNKT cell frequency and
iNKT cell-IL-4 production, while no associations were detected in patients with >3 plaque sites
or between iNKT cell phenotype and other plaque measures (fig. S6).
To investigate this further in relation to clinical cardiovascular disease we included an additional
cohort of SLE patients that had suffered a cardiovascular event (SLE-CV). Table S56 details the
SLE-CV patient characteristics; no differences in serum lipid profile were detected between the
14
SLE-P and SLE-CV groups or between SLE-P patients with 1-2 vs 3-4 plaque sites (fig.S7A-D).
However, SLE-CV patients, had a different iNKT cell phenotype, characterized by low PB
frequency, increased CD8+ phenotype, reduced CD69 expression and low ex vivo expression of
IL-4 and IFN-ɣ compared to SLE-P and SLE-NP patients (Fig. 5A-G). This was associated with 
increased expression of pro-inflammatory monocytes (CD14++CD16+) and reduced M2-like
monocyte frequency (Fig. 5H-J). Stratification of SLE-P patients according to number of plaque
sites revealed a trend towards reduced iNKT cell frequency and activation in patients with more
than three plaque sites similar to patients with clinical CVD (Fig. 5A-J and S7D).
Thus SLE patients with different stages of atherosclerosis development had distinct iNKT cell
phenotypes (Fig. 5K). In particular iNKT cells from SLE-CV patients had a ‘non-activated’ ex
vivo phenotype and did not proliferate in response to αGalCer stimulation (Fig S7E). Hence we 
suggest a potential mechanism whereby in SLE-P patients anti-inflammatory iNKT cell
responses, potentially driven by dyslipidaemia and altered phospholipid-antigen presentation,
reflect an attempt to resolve inflammatory processes during early plaque formation. In patients
with clinical cardiovascular disease, iNKT cells lost their anti-inflammatory potential and had an
‘inactive’ phenotype (Fig. 6A-C).
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DISCUSSION
SLE patients have an increased risk of developing both clinically apparent CVD and subclinical
atherosclerotic plaque, however, while dyslipidemia and immune dysfunction have been widely
described in patients with SLE, their role in the development of atherosclerosis is not clear. Here
we identified a protective role for iNKT cells in the immune response against early
atherosclerosis. Three key observations supported this conclusion; firstly SLE-P patients had an
iNKT cell phenotype characterized by increased activation and IL-4 production; secondly, SLE-
P patients had an altered serum lipid profile, in particular altered lipoprotein composition that
correlated with the anti-inflammatory iNKT cell phenotype and thirdly, iNKT cells differentiated
in the presence of SLE-P serum induced the polarization of atheroprotective M2
monocytes/macrophages.
The role of iNKT cells in human disease remains elusive; iNKT cells have a reduced PB
frequency in both autoimmunity, including SLE (8, 9), and atherosclerosis (26), potentially due
to iNKT cell migration to inflamed tissues (27). Beyond this little detailed information about
iNKT cell phenotype in patients with atherosclerosis exists. We revealed that SLE-P patients had
increased CD4+iNKT cell number, IL-4 production and GATA-3 expression compared to SLE-
NP patients; characteristic of NKT2 cells, a functional iNKT cell subset with anti-inflammatory
properties (28). CD4+iNKT cells have previously been isolated from human plaque tissue (26)
and associated with Th2 responses in healthy donors (29) and cancer patients (30). However,
there is no consensus on the role played by iNKT cells during preclinical atherosclerosis since
they promote fatty streak formation in LDLR-/- mice (31), but have an athero-protective role
during the early stages of plaque development via increased IL-10 production (13). We found
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that patients with clinical CVD (SLE-CV) lost the potentially protective NKT2-like phenotype
and had reduced IL-4 and IFN-γ production similar to  iNKT cells from ApoE-/- mice with
advanced plaques (11).
Our findings support marked iNKT cell phenotypic heterogeneity during human health and
disease which could be driven by factors including serum lipids or cytokines since iNKT cells
can be activated by both self and foreign antigens via the iTCR and/or or by iTCR-independent
mechanisms via cytokine stimulation, notably IL-12 and IL-18 released by APCs(32). Standard
serum lipid assessments were within normal ranges for all patients however, the metabolomic
analysis revealed a significant alteration in lipoprotein particle concentration and lipid
composition between SLE-P and SLE-NP patients, however, we did not detect differences in the
levels of IL-12 and IL-18bp (essential for IL-18 function) which are known to promote IFN-ɣ-
mediated iNKT1 responses (33). Nevertheless, changes in the balance between iTCR and
cytokine signals could play a role in the altered iNKT cell IFN-ɣ:IL4 ratio observed in SLE-P 
compared to SLE-NP patients and it would be interesting to investigate further whether the trend
towards reduced IL-12 levels in the SLE-P patients contributes to this process (32).
Differences in lipoproteins are known to predict subclinical atherosclerosis in the general
population (34). However, there is little information on lipoprotein subclasses in SLE patients
despite reports of defects in serum metabolite and lipid content (35) and reduced capacity of
serum to sustain cholesterol efflux from THP-1 macrophages (36). We are therefore the first to
identify variations in serum lipoproteins between SLE patients with and without pre-clinical
plaque suggesting that more detailed analysis of lipoprotein taxonomy could help to predict
cardiovascular risk in SLE patients.
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Although the exact mechanism linking serum lipids and iNKT cell activation in SLE-P patients
remains to be determined, we have identified a potential role for phospholipids in driving this
anti-inflammatory iNKT cell response in SLE patients. No significant differences in the
expression of lipoprotein or scavenger receptors were detected on monocytes from SLE patients
and healthy donors potentially ruling out changes in the rate of lipid uptake. We identified
differences in lipoprotein expression and lipid composition between the SLE-NP and SLE-P
patient groups and it is tempting to speculate a link between VLDL-lipid content and the
significant expansion of anti-inflammatory iNKT cells. In particular, VLDL from SLE-P serum
contained increased phospholipids, which are known to activate iNKT cells (37). However,
healthy PBMC culture with VLDL purified from SLE-P patients did not influence iNKT cell
phenotype therefore the relevance of changes in VLDL lipid composition deserve further
investigation. Importantly, VLDL heterogeneity is associated with early onset atherosclerosis in
autoimmunity (38) and enzymes involved in lipid processing and presentation including
lipoprotein lipase and the adipokine resistin, which have altered expression levels in SLE
patients (39, 40). Our results support previous observations that VLDL influences lipid
accumulation in monocytes (41), which could have further implications on CD1d-mediated lipid
antigen presentation to iNKT cells.
Despite extensive work investigating monocyte/macrophage subsets in vitro and in animal models of
atherosclerosis, evidence of their patho-physiological relevance in a clinical setting remains uncertain
(21). Previous studies on human plaques demonstrate the presence of both M1 and M2
macrophages during developing atherosclerosis with a role for M2 macrophages during early
stages (24, 42). Using the monocyte phenotype described by Fadini et al (20),we show higher
frequencies of M2-like monocytes in PB from SLE-P patients compared to both SLE-NP patients
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and SLE-CV patients. This was in contrast to Fadini et al who reported increased M1-like
monocytes and decreased M2-like monocytes in patients with Familial and Non-familial
hypercholesterolemia with asymptomatic plaque (but no history of autoimmunity). However, the
severe dyslipidemia in these patients was not seen in the SLE patients from our study, whose
serum lipids were all within the standard normal range used in clinical practice.
The M1:M2-like monocyte ratio was increased in SLE-P compared to SLE-NP patients driven
by increased M1 and reduced M2-like monocyte frequencies in SLE-NP patients. SLE-P serum
was able to induce M2-like macrophage polarization but only in the presence of iNKT cells. This
finding corroborates previous observations in experimental autoimmune encephalomyelitis,
where iNKT cell deficient mice have fewer M2 macrophages and worse disease (43). Similarly,
in a mouse model of obesity α-GalCer treatment significantly increased both iNKT cell numbers
and M2 macrophage polarisation mediated by in part by IL-4 (44). We observed increased
CD206 and reduced STAT-1 gene expression in adherent healthy macrophages from PBMC
cultures with SLE-P serum and in THP-1 macrophages upon co-culture with iNKT cells
preconditioned using SLE-P serum. Although CD206 gene expression is known to be
upregulated in response to IL-4 (23, 45), blocking IL-4 increased M1 gene expression (STAT-1
and CD80) but had no effect on CD206. This suggests that iNKT cell-monocyte/macrophage
cross-talk and the promotion of M2 macrophage differentiation is a more complex mechanism
potentially involving other cytokines including IL-13, which was increased in response to F5
lipid stimulation (Fig. 3E), and transactivation of other cell types (18, 44). Conversely, during
the later stages of atherosclerosis (in SLE-CV patients and in SLE-P patients with 3-4 plaque
sites), this protective response appeared to be reduced or overwhelmed leading to iNKT cell
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exhaustion, reduced anti-inflammatory M2-like monocytes and increased pro-inflammatory
‘intermediate’ monocyte populations, in line with studies showing a predominance of M1
macrophages in more advanced rupture prone lesions (46-48) where the immune balance shifts
from tissue repair towards chronic inflammation.
A limitation of this study is the lack of ultrasound scan data for HCs and SLE-CV patients.
However, follow up scans of SLE-NP and SLE-P patients and reassessment of their
cardiovascular disease history and metabolomics status will enable more detailed evaluation of
how iNKT cells either protect against or promote atherosclerosis at different stages of the disease
in SLE patients. Furthermore, it remains to be determined whether changes in serum lipids in
SLE-P patients are potent enough to support a protective iNKT-cell mediated immune response
in vivo, whether this is specific to plaque sites or whether the protective iNKT cell phenotype is
common to patients with atherosclerosis in other autoimmune diseases or atherogenesis in the
absence of autoimmunity.
In summary, we show that iNKT cells could play a key role in linking the immune system, lipids
and CVD in patients with SLE. This supports the development of new diagnostic and
therapeutic targets for patients at increased cardiovascular risk. Close monitoring of iNKT cell
phenotype and/or serum lipid levels, since serum lipoprotein taxonomy was able to cluster
patients with and without pre-clinical plaque, could represent a novel ‘barcode’ to predict
atherosclerosis development in SLE patients and in other at risk patient groups.
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MATERIALS AND METHODS
Study Design
SLE patients have an increased risk of developing clinically apparent CVD and subclinical
atherosclerotic plaque, detectable by vascular ultrasound. Although dyslipidemia and immune
dysfunction are widely described in SLE, their role in atherosclerosis is unclear. We propose that
iNKT cells, responding to CD1d-lipid antigens presented by APCs, play a key role in linking the
immune system, lipids and CVD in SLE patients. Vascular ultrasound on 100 patients with SLE
but no history of CVD showed 36% had pre-clinical plaque. The study had research ethics
committee (06/Q0505/79) approval. Informed consent was obtained from all participants.
Patient samples (SLE-P, SLE-NP and HC) were randomly assigned to experimental groups. No
statistical methods were used to predetermine sample size which was chosen using records of
variance in past experiments.
In controlled laboratory experiments PBMCs and serum from SLE-NP, SLE-P and HCs were
used to assess iNKT cell and CD1d+-APCs phenotype and function by flow cytometry which
was performed routinely during the 3 year study. For comparison SLE patients and who had
suffered a cardiovascular event were recruited subsequent to collection of the original cohort.
Serum metabolomics was performed on all scanned patients by nuclear magnetic resonance and
lipids were purified from APCs by chloroform/methanol isolation. Gene expression was
analyzed using qPCR. In vitro cell culture experiments were performed on at least 3 separate
occasions with different HCs and SLE patient cells and serum. Data was grouped (SLE-P, SLE-
NP and HC) for analysis. Details of exact sample numbers for each experiment are detailed in
the figure legends.
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Patients and controls
Carotid and femoral ultrasound scans were performed on 100 patients who met America College
of Rheumatology criteria for SLE (49) and had no previous history of CVD. Absence of CVD
(defined as coronary artery disease, stroke or myocardial infarction with confirmatory evidence
from blood tests and/or imaging) was confirmed by analysis of medical records. See
supplementary methods for details of scanning. Eleven SLE patients who had suffered
cardiovascular disease events (SLE-CV) and 50 HCs were recruited but were not scanned
because ethical approval was not available. Clinical, demographic, serological, therapy and
disease activity characteristics for SLE-P and SLE-NP patients, HCs (table S1) and SLE-CV
patients (table S5) are shown.
Cell culture
PBMCs (5x106) were cultured for 0-7 days (ds) in complete medium (RPMI 1640, 10-50%
pooled human sera (PHS), 1% penicillin/streptomycin (Sigma)). For α-GalCer-induced iNKT 
cell expansion, 100ng/ml α-GalCer (Alexis Biochemicals) and 200IU/ml IL-2 (R&D Systems) 
was used. In some cases 5x106 PBMC were cultured for 7ds, in 50% serum from HCs or SLE
patients ±anti-CD1d (10μg/ml) (BD Pharmingen) or ±anti-IL-4 (InvivoGen) or appropriate 
isotype controls where indicated. Alternatively, PBMCs were cultured with lipid fractions
isolated from HC, SLE-NP or SLE-P B cells or monocytes for 7ds (1:100 in complete medium,
IL-2, ±anti-CD1d/isotype as indicated).
Monocyte/macrophage polarization: CD14+monocytes were negatively isolated and CD3+T
cells (including iNKT cells) were positively isolated using magnetic beads (EasySep; Stemcell
Technologies) or THP-1 cells were used as APCs. Co-cultures had 1monocyte:2 T cells with
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minimum 5x106 cells/well. Cell culture supernatants were collected and analysed by Cytometric
Bead Array (CBA) (BD) according to manufacturer’s instructions.
THP-1 co-culture: THP-1 cells (human monocytic cell line), 400,000 cells/mL in 6-well plates
were cultured for 72hs in complete medium, 20ug/mL gentamycin and 5ng/mL phorbol-12-
myrisate 13-acetate (PMA) (Sigma), washed with PBS and rested for 24hs in complete medium.
PBMCs from HCs were incubated for 4ds with serum from heterologous HCs, SLE-NP or SLE-
P patients to differentiate iNKT cells. CD3+ T cells (including iNKT cells) were positively
selected using the EasySep magnetic isolation and 1.5x106 cells were co-cultured with THP-1
macrophages. After 40hs, medium and T cells were removed, THP-1 cells were washed once
with PBS and lysed in TRIzol (Invitrogen) for RNA extraction.
Flow Cytometry
iNKT cell and monocyte phenotyping: 5x10⁶ PBMCs were surface stained in cold FACS buffer
(PBS; 1%FCS; 0.01% NaN₃; 0.5% EDTA), using the following antibodies (from Biolegend
unless indicated): iTCR-PE(6B11) (BD Bioscience) and CD3-APC/efluor780 (eBioscience) for
iNKT cells, with subsets CD4-BV605 and CD8-BV705 and CD25-alexafluor700, CD69-BV785
and PD-1-PE/Cy7, CD161-BV421, and CCR6-FITC (eBioscience) and for monocytes CD14-
efluor450, CD16-APC, CD68-PE/Cy7, CX3CR1-FITC, CCR2-PerCP/Cy5.5, and CD206-PE.
Cells were incubated at 4°C for 20 minutes, washed, fixed with 2% paraformaldehyde and re-
suspended in FACS buffer for analysis.
iNKT cell intracellular cytokine staining: PBMCs were cultured for 4 hours with 50ng/ml PMA,
250ng/ml ionomycin and 1:1000 Golgiplug (BD Bioscience) then washed and surface stained for
iNKT cells, fixed, permeabilised (eBiosciences) and stained intracellularly with IFNγ-efluor450 
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(eBioscience) and IL-4-APC. iNKT cell proliferation was assessed by intracellular staining for
Ki-67-PE (BD Bioscience) or transcription factors T-bet-PerCP/Cy5.5 and GATA-3-alexa647.
Flow cytometry acquisition using a BD LSR II flow cytometer acquiring 1-5x10⁶ cells per
sample, data analyzed using FlowJo version vX (TreeStar).
Phospholipid detection
Phospholipids were detected using HCS LipidTOXTM Phospholipidosis Detection Reagent
(Invitrogen) according to manufacturer’s instructions and flow cytometry.
Lipid isolation
Cellular lipids isolated from 1x107 FACS-sorted and PBS-washed B cells and monocytes by
chloroform:methanol extraction (v/v) (50) and fractionation using Amino Propyl
columns(Sigma). Nitrogen-dried lipids reconstituted in 500μl chloroform were added to columns 
and eluted accordingly: F1: 2 ml diethyl-ether; F2: 1.6 ml CHCl3:MeOH (23:1 v/v); F3: 1.8 ml
di-isopropylether:acetic acid (98:4 v/v); F4: 2 ml acetone:MeOH (9:1.2 v/v); F5: 2 ml
CHCl3:MeOH (2:1 v/v); F6: 2 ml 0.2 M CH3COONH4 in MeOH and 2 ml dH2O. Fractions
were dried under nitrogen, stored at -80°C and resuspended in 50µl DMSO prior to cell culture.
LDL/VLDL purification kit (Cell Biolabs) was performed according to manufacturer’s
instructions followed by dialysis in PBS (Pierce) and protein quantification using BCA assay
(Pierce).
Metabolomics
24
Serum metabolomics analysis was performed by Brainshake (Prof Ala-Korpela, University of
Eastern Finland) using a biomarker analysis platform (51). Metabolite quantification was by
proton nuclear magnetic resonance (NMR) using two spectral windows LIPO and LMWV giving
lipoprotein subclass distribution and low molecular weight metabolites. Models were cross-
validated against NMR-independent lipoprotein and lipid data, and verified to lie within a 10%
limit of the training data set.
qPCR
RNA extraction and cDNA synthesis: Cells were lysed in TRIzol. RNA extraction used RNeasy
Micro Kits (Qiagen) and quantified using Nanodrop Spectrophotometer. All 260/280 and
260/230 ratios were >1.9. cDNA from 1000ng RNA using AffinityScript QPCR cDNA
Synthesis Kit (Agilent Technologies). qPCR performed using Stratagene Mx3005P qPCR system
and Brilliant III SYBR Green Mastermix (Agilent Technologies). Intron spanning or flanking
primer pairs (Sigma Aldrich) for CD206, CD200R, STAT-1, CD80 and PPBP designed using
Primer-3 and BLAST search performed to ensure specificity. Primers were validated and used at
100nM.
Statistics
Values expressed as absolute mean ± SEM. Analysis performed using GraphPad Prism
(GraphPad Software) using 2-tailed Student’s t test, paired Student’s t test, One-way ANOVA
and Tukeys multiple comparison post T- tests or Pearson’s correlation as specified. P= <0.05
were considered significant. Normal distribution tested using Kolmogorov-Smirnov test.
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FIGURE LEGENDS
Figure 1: SLE patients with sub-clinical plaque had a distinct iNKT cell phenotype. Ex vivo
iNKT cell frequency in PBMCs. (A) Representative flow cytometry dotplots and (B) cumulative
data showing mean iNKT cell absolute numbers (**p=0.001; *p=0.01) and percentage (HC vs
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SLE-NP, *p=0.01; SLE-NP vs SLE-P, *p=0.03; HC, n=50, SLE-NP, n=35, SLE-P, n=30; One-
way ANOVA post-T tests).
Intracellular IL-4 expression in ex vivo iNKT cells (C) Representative dotplots and (D)
cumulative data showing IL-4+ iNKT cells (%) and (E) ratio of iNKT cells producing IFN-ɣ 
compared to IL-4. FMO=fluorescence minus one control. (HC vs SLE-P, *p=0.01; SLE-NP vs
SLE-P, *p=0.05; HC n=11, SLE-NP n=21, SLE-P=21; One-way ANOVA post-T tests).
Ex vivo iNKT cells were stained intracellularly with either T-Bet or GATA-3. (F) Representative
histogram and (G) cumulative data including T-bet:GATA3 ratio. (GATA3: *p=0.01, HC n=3,
SLE-P n=5, SLE-NP n=5; One-way ANOVA post-T tests; T-Bet:GATA3 ratio *p=0.05 paired T
test).
iNKT cell proliferation (Ki-67 expression) after 7d culture with α-GalCer and IL-2. (H) iNKT
cell Ki-67 expression at d0 and 7d culture (HC *p=0.01; SLE-P, *p=0.02; HC n=5, SLE-NP n=7,
SLE-P n=7, paired T test). (I) iNKT cell Ki-67 expression mean fluorescence intensity (MFI) at
d7 (*p=0.01, HC n=6, SLE-NP n=8, SLE-P n=9, One-way ANOVA post-T test). (J) Fold
change in iNKT cell frequency at d7 compared to d0 (*p=0.04, HC n=4, SLE-NP n=7, SLE-P
n=8, One-way ANOVA post-T test). (K) iNKT cells positive for ICOS and CD40L expression
(%) at d7 (*p=0.01, HC n=3, SLE-NP n=5, SLE-P n=5; One-way ANOVA post-T test). NS=not
significant.
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Figure 2: Dyslipidaemia was associated with altered iNKT cell activation in SLE-P
compared to SLE-NP patients. PBMCs from 4 healthy donors were each cultured with 50%
serum from 5 heterologous HCs, 5 SLE-P or 5 SLE-NP patients +IL-2. At d0, d4 and d7 iNKT
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cell frequency and intracellular IL-4 production were analysed by flow cytometry. (A)
Representative dotplots showing iNKT cell frequency at d7 and (B) line graphs showing
individual experiments (d7 Healthy donor 1-3, HC vs SLE-P, *p=0.05; n=5, One-Way Anova
post-T test). (C) Cumulative data showing % change in iNKT cell frequency at d7 compared to
d0 (*p=0.01, **p=0.001; n=16, One-Way Anova post-T test). (D) Cumulative data showing the
percentage of iNKT cells producing IL-4 at d7 (*p=0.05; n=10, One-Way Anova post-T test) (E)
Culture of PBMCs from a healthy donor with serum from six different healthy donors, SLE-NP
and SLE-P patients ± blocking anti-CD1d antibody or isotype control (*p=0.05; n=6, paired-T
test).
Serum from 33 SLE-P and 53 SLE-NP patients were analysed by proton nuclear magnetic
resonance spectroscopy for 230 serum lipid metabolites. (F) Lipoprotein size and composition
between SLE-P and SLE-NP patients compared using a Students T test, converted into log-10 p
value and plotted as a heat map. Higher log-10 p values (red) represent greater differences
between metabolites in SLE-P compared to SLE-NP patients (Table S2, Figure S3 and S4). (G)
Serum metabolite levels were correlated with iNKT cell frequency for SLE-P and SLE-NP
patients (Table S4). Volcano plot showing Pearson’s correlation (r) vs metabolite expression
(log-10 p values) in SLE-P and SLE-NP patients. Dotted line represents p=0.05. FA=fatty acid;
MUFA=monounsaturated fatty acid. (H) Correlation between iNKT cell intracellular IL-4
expression and serum triglycerides (left-panel) and total cholesterol:HDL ratio (right panel)
(Table S3). IL-4 vs triglycerides, SLE-P; n=28, r=0.581, p=0.005; SLE-NP; n=23 r=-0.390,
p=0.07: IL-4 vs total cholesterol:HDL, SLE-P, n=21, 0.546, p=0.01, Pearson’s correlation. (I)
Serum metabolite levels were correlated with iNKT cell intracellular IL-4 expression for SLE-P
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and SLE-NP patients (Table S4). Volcano plot showing Pearson’s correlation (r) vs metabolite
expression (log-10 p values) in SLE-P and SLE-NP patients. Dotted line represents p=0.05.
HC PBMCs were cultured for 48h in RPMI/50% PHS, isolated serum VLDL/LDL from HC,
SLE-NP and SLE-P patients, or propranolol (positive control) +LipdToxTM phospholipidosis
detection reagent and analysed by flow cytometry. (J) Representative histograms showing serum
culture and MFI values and (K) cumulative data (*p=0.01, n=3, One-Way Anova post-T test).
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Figure 3: Altered lipid-antigen presentation by monocytes from SLE-P patients drives
increased iNKT cell frequency and IL4 production. (A) Experimental plan: B cell and
monocyte lipids from HC, SLE-NP or SLE-P donors were isolated by chloroform: methanol
extraction, and fractionated using Amino Propyl Columns (F1-F6). PBMCs from 4 HCs were
stimulated with each lipid fraction +IL-2. iNKT cells were quantified by flow cytometry at d0,
d4 and d7. (B) Cumulative data (F1 vs F5, p=0.05, F2 vs F5, p=0.05, F3vs F5 p=0.01, F4 vs F5
p=0.05, F6 vs F5*p=0.05: n=4, One Way ANOVA, T-tests).
Fraction 5 (F5) lipids from monocytes and B cells were used to stimulate PBMCs from five HCs
+IL-2 for 7ds. At d7 cell culture supernatants were collected and iNKT cell frequency assessed.
(C) Representative flow cytometry dotplots showing iNKT cell frequency in response to
monocyte derived F5 lipids compared to vehicle (DMSO). (D) Cumulative iNKT cell frequency
in response to monocyte-derived and B cell-derived F5 lipids (*p=0.04, ***p=0.0001;
**p=0.006; n=5, One-way ANOVA post T-Tests) (E) Cell culture supernatants from d7 cultures
with monocyte F5 lipids were assessed for IL-4, IL-13 and IFN-ɣ by CBA. Cumulative data (IL-
4, *p=0.04; IL-13, *p=0.05; IFN-ɣ, *p=0.05, n=5 Paired T test). The experiment described in
(C-GF) was repeated ± blocking anti-CD1d antibody or isotype control. (F) Representative flow
cytometry dotplots showing iNKT cell expansion. (G) CBA data of IL-4, IL-13 and IFN-ɣ 
expression in tissue culture supernatants following 7d culture with SLE-P F5 monocyte lipids ±
anti-CD1d or isotype control, compared to vehicle (DMSO) and αGalCer as negative and 
positive controls (IL-4, **p=0.001; IL-13, **p=0.004, n=6, Paired T test).
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Figure 4: iNKT cells from SLE patients with pre-clinical plaque support M2 macrophage
differentiation
PBMCs were surface stained for monocyte subpopulations. (A) Representative flow cytometry
dotplots and (B) cumulative data for CD14+CD16+ monocyte frequency (HC *p=0.5; ** p=0.01,
HCs n=10, SLE-NP n=20, SLE-P n=20; One Way ANOVA post T test). Representative plots
for (C) CD14+CD68+CCR2+ M1-like and (D) CD14+CD206+CX3CR1+ M-2-like monocyte
populations, (E) ratio of CD68+CCR2+ to CD206+CX3CR1+ monocytes (*p=0.05; **p=0.004; T-
tests) and (F) cumulative data (M1-like: *p=0.05; HC vs SLE-P, **p=0.01; M2-like; *p=0.01;
*p=0.002, HCs n=10, SLE-NP n=20, SLE-P n=20; One Way ANOVA post T test).
Monocytes from 6 HCs were negatively isolated and cultured with RPMI containing 50% HC,
SLE-NP or SLE-P serum for 7ds. Adherent differentiated macrophages were recovered. (G)
Representative plots showing CD206 expression on CD68+Macrophages. FMO=fluorescence
minus one control. (H) CD206 expression on CD68+ macrophages (MFI) (left-hand panel);
percentage of CD68+ macrophages positive for CD206 (centre); ratio of M1: M2 macrophages
(right-hand panel). (I) Experimental plan: Purified monocytes (105/well) and T cells
(7.5x105/well) from HCs were co-cultured with 50% serum from 6 SLE-NP, 6 SLE-P patients
and 6 HCs for 7ds. At d7 adherent differentiated macrophages were recovered. (J) Cumulative
flow cytometry data showing frequency of M2-polarised macrophages (CD68+CD206+)
(*=p=0.008; *p=0.015, n=3 One Way ANOVA post paired T-test) and (K) RNA was analyzed
for CD206 and STAT-1 gene expression by qPCR (CD206, *p=0.050; STAT-1, *p=0.049, n=4
paired T test).
(L) Experimental plan: PBMC from 2 HCs were cultured with 50% serum from 3 different HCs,
3 SLE-NP and 3 SLE-P patients for 7ds to induce iNKT cell differentiation. Isolated CD3+ T
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cells (including iNKT cells) were co-cultured with differentiated THP-1 human macrophage cell
line for 40hs. Macrophages were analyzed for expression of M1 and M2- associated genes by
qPCR. (M) Cumulative data showing M2 (CD206 and CD200R) and M1 (STAT-1, PPBP,
CD80) gene expression normalised to the level of cyclophilin (45) (CD206, *p=0.049; STAT-1,
HC vs SLE-P, *p=0.011, SLE-NP vs SLE-P, *p=0.049, n=4, One Way Anova and post T test).
Healthy donor PBMCs (n=2) were cultured for 7ds with PHS from 5 HCs, 5 SLE-NP and 5 SLE-
P patients or IL-4 ± anti-IL4 blocking antibody or isotype control. RNA from adherent
macrophages was analyzed by qPCR. (N) Combined cumulative data for STAT-1, CD80 and
CD206 expression, (STAT-1, *p=0.050, CD80, * p=0.039; n=6, Paired T tests) and (O) fold
change gene expression compared to isotype (isotype=1) for macrophages cultured in HC, SLE-
NP and SLE-P serum.
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Figure 5: iNKT cells from SLE patients with clinical cardiovascular disease were anergic
and associated with pro-inflammatory monocytes.
Ex vivo iNKT cell frequency and phenotype in SLE-NP, SLE-P patients (stratified according to
number of plaque sites; 1-2 and >3 plaque sites) and SLE patients who had previously suffered a
cardiovascular event (SLE-CV), Table S5. (A) Representative dot plots and (B) cumulative data
showing iNKT cell % and absolute number (**p=0.01; *p=0.05; SLE-NP n=46, SLE-P(1-2)
n=15, SLE-P(>3) n=10, SLE-CV n=9; One way ANOVA post-T test) (C) frequency of iNKT
cell CD8+ (*p=0.05; **p=0.001) and CD8-CD4- subsets (*p=0.01; SLE-NP n=18, SLE-P(1-2)
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n=10, SLE-P(>3) n=10, SLE-CV n=5; One way ANOVA post-T test) (D) Representative
histograms and (E) cumulative data showing CD69+ iNKT cells (%) (*p=0.05; SLE-NP n=32,
SLE-P(1-2) n=14, SLE-P(>3) n=10, SLE-CV n=8, One way ANOVA post-T test). (F)
Representative dot plots and (G) cumulative data showing frequency of IFN-γ+ and IL-4+ iNKT
cells (IL-4: *p=0.05; **p=0.01; IFN-ɣ: *p=0.05; **p=0.01; SLE-NP n=23, SLE-P(1-2) n=15, 
SLE-P(>3) n=11, SLE-CV n=5, One way ANOVA post-T test).
Analysis of monocyte subsets in ex vivo PBMCs. (H) Representative dot plots and (I) cumulative
data for CD14+CD16+ intermediate monocytes (%) (*p=0.03; **p=0.01; 20 SLE-NP n=20, 17
SLE-P(1-2) n=10, SLE-P(>3) n=7, SLE-CV n=8; one way ANOVA post-T-test) (J) Cumulative
data for M1-like (CD68+CCR2+) monocytes, M2-like (CD206+CX3CR1+) monocytes (*p=0.05)
and M1:M2 ratio (*p=0.04; **p=0.008, SLE-NP n=14, SLE-P(1-2) n=10, SLE-P(>3) n=4, SLE-
CV n=8; one way ANOVA post-T-test). (K) Summary of iNKT cell heterogeneity in SLE-NP,
SLE-P and SLE-CV patients relative to HCs.
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Figure 6: Proposed mechanism of iNKT cell activation in SLE patients with early
atherosclerosis. Dyslipidaemia could contribute to an initial protective iNKT cell response in
SLE-P patients, mediated by M2-associated cytokines (including IL-4 and IL-13) and activation
of M2 macrophages. (A) In SLE-NP patients: CD1d-lipid presentation induced iNKT cells
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characterized by reduced frequency, CD4low, CD69low, CD161high, PD-1high and low IL-4
production, supporting inflammatory M1-macrophage polarization. (B) In SLE-P patients:
altered presentation of phospholipids induced iNKT cells characterized by increased iNKT cell
frequency, CD4high, CD69high, CD16low, PD-1low and elevated IL-4 production, potentially
supporting M2-macrophage polarization. (C) In SLE-CV patients: continued activation could
overwhelm the protective iNKT cell response resulting in an unresponsive phenotype
characterized by reduced frequency, CD8high, CD161low, PD-1low and CD69low and reduced IFNγ 
and IL-4 production and a subsequent failure to induce M2 macrophage polarization.
